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Playing a central role in the modern multidisciplinary management of acute gastroesophageal variceal hemorrhage, endoscopy is
essential to stratify patient at risk, control active hemorrhage, and prevent ﬁrst as well as recurrent bleeding. Before endoscopic
procedure, antibiotic prophylaxis along with vasoactive medication is now routine practice. Intravenous erythromycin eﬀectively
cleanses stomach and may improve the quality of endoscopy. The timing of endoscopy should be on an urgent basis as delay for
more than 15 hours after presentation is associated with mortality. Active variceal bleeding on endoscopy in a patient with hepatic
decompensation heralds poor prognosis and mandates consideration of aggressive strategy with early portosystemic shunting.
Band ligation has become the preferred modality to control and prevent bleeding from esophageal varices, although occasionally
sclerotherapy may still be used to achieve hemostasis. Addition of pharmacotherapy with nonselective beta blockade to endoscopic
ligationhasbecomethecurrentstandardofcareinthesettingofsecondaryprophylaxisbutremainscontroversialwithinconsistent
data for the purpose of primary prophylaxis. Gastric varices extending from esophagus may be treated like esophageal varices,
whereas variceal obliteration by tissue glue is the endoscopic therapy of choice to control and prevent bleeding from fundic and
isolated gastric varices.
1.Introduction
Acute variceal hemorrhage (AVH) from esophageal varices
(EV) or gastric varices (GV) is a devastating complication
of portal hypertension. It is a leading cause of death
in cirrhotic patients, particularly in those with hepatic
decompensation. Early cohort studies observing the natural
course of patients with AVH revealed that the short-term
mortality rate was as high as 50%, with uncontrolled active
hemorrhage and recurrent bleeding as the major causes of
death [1–3]. As a witness of progress in modern medicine,
the prognosis of AVH has remarkably improved for the last 3
decades, although the short-term mortality (conventionally
deﬁned as within 6 weeks of each episode) in recent
series remained approximately 15–20% [4]. The improved
outcome of cirrhotic patients with AVH probably results
from advancement in the multidisciplinary approaches that
include pharmacological therapy (vasoactive agents, antibi-
otic prophylaxis), endoscopic intervention (band ligation for
EV, variceal obliteration for GV), transjugular intrahepatic
portosystemic shunt (TIPS), and surgery. Being an essential
part in the management of acute upper gastrointestinal
(UGI) bleeding, endoscopy plays important roles in the
conﬁrmation of bleeders, stratiﬁcation of risks, control of
active hemorrhage, and prevention of the ﬁrst and recurrent
bleeding in cirrhotic patients with AVH [5]. The purpose of2 International Journal of Hepatology
this paper is to provide a concise and updated review on the
use of endoscopy in managing patients with AVH.
2. Preparationfor Endoscopy in
CirrhoticPatients withAcute UGIB
Patients with AVH frequently present with unstable hemo-
dynamics because bleeding characteristically occurs not
only massively but also rapidly. Therefore, restoration of
circulatory volume by intravenous ﬂuid resuscitation should
becarriedoutimmediatelyatpatients’arrival.Bloodcompo-
nent therapy usually is needed to correct anemia and bleed-
ing tendency (coagulopathy as well as thrombocytopenia).
Vasopressormayoccasionallyberequiredtomaintainhemo-
dynamic stability. A quick assessment for the indications of
airway protection by endotracheal intubation is mandatory,
in that the concern of suﬀocating aspiration is substantial in
patients with massive hematemesis, impaired consciousness,
and delirious status. Ideally, risks of circulatory collapse and
airway compromise should be minimized before patients are
transported to endoscopy rooms.
Intravenous administration of erythromycin prior to
endoscopymaybeconsideredincirrhoticpatientspresenting
with hematemesis, because brisk bleeding and large quantity
of residual blood in the UGI tract often obscure endo-
scopic views, add diﬃculty of therapeutic intervention, and
increase chance of aspiration. As a motilin receptor agonist,
erythromycin induces peristalsis, stimulates gastrointestinal
motility, and shortens gastric emptying time. The eﬃcacy of
erythromycin in cleansing stomach and thereby improving
quality of endoscopy has been demonstrated in randomized
controlled trials [6–8]. Recently, Altraif and colleagues
reported in a double-blind randomized trial that ery-
thromycin of 125mg intravenously administered 30 minutes
before endoscopy as compared with placebo signiﬁcantly
increased the proportion of a clear stomach (48.9% versus
23.3%, P<. 01), decreased the mean procedural duration
(19.0 minutes versus 26.0 minutes, P<. 05), and shorten
the hospitalized days (3.4 days versus 5.1 days, P<. 02) in
cirrhotic patients with AVH [7]. Besides, this medication
appeared safe in these vulnerable patients without speciﬁc
adverse reactions. Nevertheless, it remains unclear whether
erythromycin also helps in controlling active hemorrhage,
preventing recurrent bleeding, or adding survival beneﬁt.
So far, erythromycin infusion before endoscopy has not
become a routine practice in most hospitals including
ours. Finally, vasoactive agents (terlipressin, octreotide, and
somatostatin) and prophylactic antibiotics before endoscopy
unambiguously improve clinical outcomes and are now
considered as an integral part of the evidence-based standard
of care in cirrhotic patients presenting with acute UGI
bleeding [9–11].
3. Timing of Endoscopy
The optimal timing of endoscopy for patients with AVH
has long been controversial. Earlier randomized controlled
trials for patients with esophageal variceal bleeding found
that endoscopic sclerotherapy as compared with vasoactive
pharmacotherapy (terlipressin, somatostatin) was not more
eﬀective in terms of hemostasis rate, prevention of recurrent
bleeding, or prolonging survival, but was associated with
more adverse eﬀects [12, 13]. D’Amico and colleagues thus
concluded in a meta-analysis study that endoscopic therapy
c o u l db er e s e r v e df o ru s ea f t e rp h a r m a c o l o g i c a lt r e a t m e n t
failed in EV bleeding [14]. However, this conclusion has
become less clinically relevant after band ligation replaced
sclerotherapy as the endoscopic therapy of choice for EV
bleeding. Solid evidence supports the former was not only
more eﬃcacious but also safer than the latter [15]. Fur-
thermore, since endoscopic plus pharmacological therapy is
superior to either treatment alone and pharmacotherapy can
be readily given before endoscopy [16, 17], it is no longer
valid to suggest reserving endoscopic intervention (particu-
larly band ligation for EV bleeding) after failure of vasoactive
drugs. What remains unsettled is how urgently endoscopy
should be performed in patients already receiving optimal
medical therapy. Practice guidelines from the international
conference (the Baveno workshop) for the management
of AVH recommended UGI endoscopy be performed as
soon as possible (<12 hours) after admission [18, 19].
However, this recommendation was supported not so much
byobjectivedataasbyexperts’rationalconsensus.Toaddress
this unresolved issue, we conducted a retrospective analysis
of 311 consecutive cases with AVH to examine whether
timing of endoscopy was associated with mortality [20].
We found that timing of endoscopy was correlated with
in-hospital mortality (Figure 1). In multivariate analysis,
delayed endoscopy (>15 hours after presentation to the hos-
pital) was an independent risk factor associated with mortal-
ity (odds ratio 3.67; 95% conﬁdence interval, 1.27∼10.39).
Our study, nonetheless, failed to demonstrate “the sooner
the better” concept, in that the association between risk of
death and endoscopy timing was nonlinear and mortality
did not decrease with every hour earlier of endoscopy.
Somewhat inconsistent with our observation, Cheung et al.
from Canada reported that endoscopy timing was unrelated
with clinical outcomes in hemodynamically stable AVH
patients[21].Theyfoundwhetherendoscopywasperformed
within 4, 8, or 12 hours within initial assessment at hospital
didnotinﬂuencerecurrentbleeding,bloodtransfusion,need
for rescue therapy, length of hospitalization, or mortality. Of
note, only half of all patients with AVH were enrolled into
analysisintheirstudy,becausetheresultsofthosewithinitial
unstable hemodynamics were not reported [22]. In view
of the understandable diﬃculty to perform a randomized
trial to compare diﬀerent endoscopy timings in this setting,
the controversy will probably continue to exist. Based on
currently available data, we believe the rule is to perform
endoscopy within 15 hours of presentation, but meanwhile
we also acknowledge there is no evidence to support rushing
endoscopy in AVH patients, particularly in those with stable
hemodynamics. Therefore, while delaying endoscopy for
more than 15 hours should be avoided, endoscopists may
wait in the ﬁrst few hours to allow emergency resuscitation,
optimal medication, and perhaps preparation for a cleaner
stomach to be carried out.International Journal of Hepatology 3
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Figure 1: Receiver operating characteristic curve of “door-to-
scope” time for in-hospital mortality. The area under curve is
0.696 (95% C.I. 0.595∼0.797). The most optimal cut-oﬀ value
(in integer) to predict in-hospital mortality was 15 hours, with
sensitivity of 72.0% and speciﬁcity of 59.4% (adapted from [20]).
4. Risk Stratiﬁcation withand
without Endoscopy
Determination of bleeding source by upper GI endoscopy
has important prognostic value in cirrhotic patients with
acute UGI bleeding, since patients with variceal bleeding
(deﬁnite or probable) fared signiﬁcantly worse than those
who bleed from other sources [23, 24]. In addition, active
bleedingonendoscopywasshowntopredict5-daytreatment
failure and 6-week mortality [24, 25]. With regard to the
risk prediction for patients with endoscopically conﬁrmed
AVH, measurement of hepatic venous pressure gradient
(HVPG) is arguably the best method to stratify risk of
untoward outcomes. It has been demonstrated that an initial
HVPG>20mmHg most reliably identiﬁed those patients
whose clinical course would evolve poorly [26]. Further-
more, a large body of evidence supports reduction of greater
than 20% of the initial HVPG value convincingly indicates
risk reduction in recurrent bleeding and mortality [27].
However, application of HVPG measurement is regrettably
not widespread around the world, and in reality is not
incorporated into daily practice in the vast majority of
institutions. Fortunately, there is evidence suggesting that
easily obtainable clinical variables, as compared with HVPG,
may have similar accuracy in predicting failure of treatment
during the acute phase of a bleeding episode (5 days) [28].
Among the various clinical parameters that have been inves-
tigated, indicators of hepatic reserve (Child-Turcotte-Pugh
classiﬁcation, model for end-stage liver disease (MELD)
score), markers of bleeding severity (active bleeding on
endoscopy,presentationwithhematemesis,amountofblood
transfusion, hemoglobin level), underlying liver disease
or comorbidity (etiology, hepatocellular carcinoma, portal
vein thrombosis), complications during bleeding episodes
(encephalopathy, bacterial infection, renal dysfunction), and
failure of initial treatment (uncontrolled active hemorrhage,
recurrent bleeding) have been shown to predict clinical
outcomes [20, 24, 29–32]. Endoscopic identiﬁcation of AVH
patients at risk of unfavorable outcomes may be crucial
in guiding subsequent management. Garcia-Pagan and col-
leagues reported in a randomized trial that EV patients
with hepatic decompensation (Child-Turcotte-Pugh scores
between 7 and 13) and persistent bleeding at endoscopy
would beneﬁt from early TIPS performed within 72 hours
[33]. The one-year survival rate was 86% versus 61% (P<
.001) in patients randomized to early TIPS as compared with
thosewhowereassignedtoreceiveoptimalpharmacotherapy
plus endoscopic band ligation. Therefore, it stands to reason
that patients with actively bleeding and compromised liver
function may require aggressive therapy to be implemented
as early as a continuation to endoscopic therapy rather than
as a rescue measure for treatment failure.
Although the prognostic factors for AVH have been
extensively studied, those for cirrhotic patients with all
sources of acute UGI bleeding remain sparsely explored.
Undoubtedly, endoscopy is urgently indicated in cirrhotic
patients presenting with UGI bleeding, but it takes time
to resuscitate the patients, transfuse blood components,
and administer intravenous medications. Therefore, risk
stratiﬁcation explicitly for variceal bleeding may not be
applicable for clinicians managing patients in the emergency
department, since not all cirrhotic patients bleed from
varices. Previous studies that investigated prognostic indices
independent of the source of bleeding not only incorporated
endoscopic data but also allowed subjective criteria [23,
24]. In our opinion, criteria based on subjective judgment
may not be reliable, particularly in the busy emergency
setting. For example, uncovering and staging ascites and
encephalopathy relies on expertise and is not free of inter-
observer variation [34]. We believe a useful stratiﬁcation
system in the setting of emergency room should ideally be
built on simple, objective, and readily available parameters.
To this end, we have retrospectively studied 542 consecutive
episodes of acute UGI bleeding from 389 cirrhotic patients
in order to develop a prognostic model consisting of pre-
endoscopic clinical factors that were routinely available
in the ﬁrst hour at hospital [35]. We revealed that 6-
week mortality was independently associated with male
gender, hypoxemia on arrival, hepatocellular carcinoma and
another malignancy, serum bilirubin, and prothrombin time
(Table 1). The performance of a model built on these 6
variables was superior to the MELD score in predicting 6-
week mortality, with c statistic of 0.84 and 0.71 respectively
(P = .002). Presumably, earlier risk stratiﬁcation may guide
earlier modiﬁcation of therapeutic approaches to improve
the outcomes of those at risk. Further research is now
warrantedtoelucidatehowpre-endoscopicriskstratiﬁcation
will inﬂuence the early management for cirrhotic patients
presenting with acute UGI bleeding.
5. Endoscopic Therapy for PrimaryProphylaxis
Screening endoscopy is mandatory to conﬁrm the presence,
to determine the size, and to uncover the stigmata of
varices in cirrhotic patients, particularly in those with4 International Journal of Hepatology
Table 1: Independent risk factors of 6-week mortality in cirrhotic
patients with acute upper gastrointestinal hemorrhage, determined
by multivariate logistic regression model.
Adjusted odds
ratio
95% conﬁdence
interval
Male sex 4.35 1.14∼16.62
Hypoxemia# 9.42 3.65∼24.30
HCC 2.31 1.12∼4.78
Non-HCC
malignancy 4.70 1.55∼14.26
Bilirubin (per mg/dL) 1.07 1.02∼1.13
INR (per unit) 2.88 1.28∼6.51
#Hypoxemia is deﬁned as peripheral oxygen saturation less than 95%; HCC:
hepatocellular carcinoma; INR: international normalized ration (adapted
from [35]).
decompensated status [36–38]. Historically endoscopic scle-
rotherapy had been used in preventing the ﬁrst bleeding
from esophageal varices prior to the era of band ligation
[39], but it is no longer recommended in this indication
becausetheriskofcomplicationsmayoutweighthepotential
beneﬁts [40, 41]. EVL is technically infeasible for small
e s o p h a g e a lv a r i c e sd e ﬁ n e da ss i z e<5mm or F1 according
to the classiﬁcation proposed by Beppu et al. [38], whereas
nonselective beta-blocker (NSBB) may slow the growth of
small EV and thereby prevent the ﬁrst variceal hemorrhage
[42]. In patients with medium to large (or F2-F3) EV, risk
of future bleeding is substantial and primary prophylaxis is
indicated. Band ligation is as at least eﬀective as NSBB for
primary prophylaxis of EV bleeding [43–46]. The decision
to use EVL or NSBB should be individualized according
to the local resources and expertise, patients’ preference
and characteristics, tolerability of side eﬀects, and contra-
indications to either therapy. In fact, more than half of
patients preferred EVL over NSBB use for fear of side eﬀects
from beta-blockade, such as light-headedness, shortness
of breath, fatigue, and poor memory [47]. Because poor
tolerability to NSBB is not uncommon and the response
of HVPG to pharmacological therapy cannot be reliably
assessed by clinical parameters, we usually perform EVL for
primary prophylaxis in our institutes.
There is no doubt that band ligation and NSBB are
eﬀective, respectively, to prevent ﬁrst bleeding in the EV
with medium to large size, but it remains unknown whether
combination therapy with both treatment modalities is more
eﬀective than either therapy alone. Sarin et al. reported
in a randomized controlled trial that propranolol plus
EVL and EVL alone were not diﬀerent in bleeding related
death, although there was less recurrence of varices in the
combination group (5.6% versus 15.3%, P = .03) [48]. In a
randomized trial conducted by Gheorghe et al., propranolol
plus EVL as compared with propranolol alone resulted in
lower rate of ﬁrst bleeding from the high risk EV (6%
versus 31%, P = .03), and higher bleeding-free survival rate
(96% versus 69%, P = .04) during the 18-month followup
in cirrhotic patients awaiting liver transplantation [49].
Nevertheless, Lo and colleagues demonstrated that EVL plus
nadolol was not only not more eﬀective that nadolol alone
for primary prophylaxis of EV bleeding but also associated
with more adverse events (68% versus 40%, P = .06) [50]. As
the controversy goes on, currently combination therapy with
EVL plus NSBB cannot be recommended in patients whose
EV has not bled.
6. Endoscopic Therapy to Control
ActiveBleeding
Endoscopic therapy plays a pivotal role in the hemostasis
of AVH. EVL is the recommended endoscopic therapy
whenever feasible to control active EV bleeding, because it is
unambiguously safer and more eﬀective than sclerotherapy
[51–53]. Occasionally, sclerotherapy may be substituted if
EVL is technically diﬃcult, for example, in a repeatedly
ligated esophagus with scarred mucosa that is diﬃcult to be
sucked into the cap. It is important to carefully scrutinize the
bleeding stigmata (e.g., hematocystic spot, white nipple) in
those without ongoing bleeding at endoscopy. Localization
of the origin of bleeding is essential for successful endoscopic
therapy, inasmuch asEVL should be initiated at or justbelow
the bleeding point. If the bleeder cannot be clearly localized,
ligation may start at the gastroesophageal junction and then
advance upward spirally. While active bleeding at endoscopy
mandatesimmediatehemostasis,absenceofongoinghemor-
rhage during endoscopy should not be erroneously regarded
as reassuring to reserve endoscopic therapy. In a randomized
trial, Lo and colleagues compared EVL plus terlipressin
versus terlipressin alone in cirrhotic patients presenting with
acute inactive EV bleeding and demonstrated that EVL was
eﬀective in reducing 5-day rebleeding rate (0% versus 15%,
P=.006), treatment failure rate (2% versus 24%, P=.002),
and amount blood transfusion [54]. Therefore, EVL cannot
be spared in cirrhotic patients with inactive bleeding EV at
endoscopy if another bleeding source is unlikely.
Injection therapy with tissue glue (e.g., N-butyl-2-cya-
noacrylate and 2-octyl-cyanoacrylate) to obliterate varices
has become the endoscopic treatment of choice for isolated
gastric varices (IGV) and gastroesophageal varices extending
beyond cardia (GOV2) [55]. Regrettably, there is consider-
ablylessdataregardingtheendoscopictherapyincontrolling
active GV hemorrhage, in contrast to the overwhelming
evidence supporting the role of EVL in EV bleeding. Glue
injection using cyanoacrylate for acute GV bleeding achieves
high rates of immediate hemostatsis, eventual eradication,
and low treatment failure-related mortality rate [56]. Con-
sistent results from randomized trials provide convincing
evidence to support the superiority of obliteration therapy
over either sclerotherapy [57–59], or band ligation [60, 61].
While the techniques to achieve variceal obliteration vary
in diﬀerent institutes, it has been adopted in our daily
practice to inject a mixture of N-butyl-2-cyanoacrylate and
lipiodol(1:1)withoutcontrastagent.Despitetheeﬃcacyand
generally acceptable safety proﬁle of injection therapy with
tissue adhesives, thromboembolism infrequently occurs and
represents the most fearful complication of cyanoacrylate
injection that may potentially lead to infarction of multiple
organs [62, 63]. Use of thrombin or ﬁbrin has been exploredInternational Journal of Hepatology 5
in the management of acute GV bleeding with promis-
ing preliminary results [64–66]. Theoretical advantages of
thrombin injection include biocompatibility and minimal
mucosal damage, whereas possibility of transmissible infec-
tious disease and excessive cost are major concerns. Before
data from controlled trials comparing it with cyanoacrylate
is available, thrombin injection should better be viewed as
experimental and ideally be conﬁned in the setting of clinical
studies.
7. Endoscopic Therapy for
Secondary Prophylaxis
As long as the portal hypertension persists, it is simply the
natural course of varices to rebleed, with 1-year rebleeding
rate approximating 60% [67]. Since gastroesophageal varices
result from portal hypertension and occurrence of variceal
hemorrhage depends directly on hydrostatic pressure of por-
tal system (as reﬂected by HVPG), presumably the best treat-
ment to prevent recurrent bleeding is to reduce the severity
of portal hypertension, and that is the pathophysiological
basis for the eﬃcacy of NSBB. In view of the high recurrence
rate, preventive measures for recurrent bleeding should be
instituted right after acute bleeding episode is controlled. It
is recommended that patients receive secondary prophylaxis
before they are discharged from hospital for an bleeding
episode, especially for those with large varices, red color
signs, and decompensated cirrhosis [55].
Consistent with its superior role in primary prophy-
laxis and controlling active hemorrhage, EVL remains the
preferred endoscopic treatment for secondary prevention of
EV bleeding. EVL, again, outperforms sclerotherapy in this
indication in terms of lower complication rate and higher
eﬃcacy [68–70]. Moreover, there is no evidence to embrace
the addition of sclerotherapy to EVL. Singh et al. reported in
a meta-analysis that combination of EVL and sclerotherapy
as compared with EVL alone was not more eﬀective in
preventing recurrent EV bleeding, but was associated with
higher complication events such as esophageal stricture
[71]. In our opinion, endoscopic sclerotherapy has no
role in the secondary prophylaxis of EV bleeding. With
regard to variceal obliteration by tissue adhesives, there
was a randomized trial demonstrating similar rebleeding
rates between histoacryl injection and NSBB administration,
but the former treatment was associated with a higher
complication rate (47.6% versus 10%, P<. 03) [72].
Moreover,weareunawareofanytrialcomparingeﬃcacyand
safety of glue injection with that of EVL in the secondary
prophylaxis of EV bleeding. In contrast to the scenario of
primary prophylaxis, in which combination therapy with
EVLandNSBBdoesnotfarebetterthaneithertherapyalone,
combiningendoscopictherapypluspharmacologicaltherapy
is recommended in the setting of secondary prophylaxis.
A meta-analysis including 23 studies showed that rates of
rebleeding (both from all sources and speciﬁcally from
varices) are lower with combination of endoscopic therapy
(either sclerotherapy or EVL) plus drug therapy than with
either therapy alone [73]. Therefore, cirrhotic patients
recovering from acute EV bleeding should receive NSBB
and have their varices eradicated by band ligation. In those
who are unable or unwilling to undergo EVL, the addition
of isosorbide mononitrites to NSBB appears a reasonable
option.
Usually several sessions of banding ligation is needed
in order to eradicate EV. However, the time interval of
band ligation remains an unsettled issue. Although some
studies proposed an interval of 1 to 2 weeks [69, 70,
74], others advocated an interval of 1-2 months of band
ligation for obliteration of EV [75, 76]. Yoshida et al. found
a short interval between sessions of EVL might even be
detrimental by showing that the overall rates of variceal
recurrence and additional treatment were both higher in
patients with EVL at a biweekly interval than those with
a bimonthly protocol [76]. Generally, we do not repeat
sessions of EVL within 2 weeks because prior ligation-
related mucosal ulceration may not have healed by that
time and thereby may inﬂuence the following deployment
of ligating bands. As far as eﬃcacy is concerned, TIPS may
be a more eﬀective modality than endoscopic therapy to
prevent recurrent bleeding. According to a meta-analysis,
patients undergoing TIPS had a lower rebleeding rate than
those receiving endoscopic treatment (19% versus 47%, P<
.001). The overall mortality, nevertheless, was not diﬀerent
[77]. The risk of hepatic encephalopathy, development of
shunt stenosis, and the cost of a covered stent make TIPS
traditionally considered as rescue therapy in patients with
repeated AVH. However, as aforementioned in the section
of risk prediction, early TIPS strategy (<72 hours) in high-
risk patients improves survival signiﬁcantly and may lead to
paradigm shift in the future [33].
Despite the relative paucity of data in the eﬃcacy and
safety of using endoscopy to prevent recurrent hemor-
rhage from GV, tissue adhesives injection using N-butyl-
cyanoacrylate is a reasonable choice for patients bleeding
from IGV1 or GOV2, similar to control of acute bleeding,
[55, 78]. For those who have bled from GOV1, either tissue
adhesives injection or band ligation may be used, depending
on the location of varices, technical feasibility, and expertise
of the endoscopist. Unless it is technically infeasible, we
recommend band ligation for EV and GOV1 at the same
time.
8. Conclusion
Endoscopy is essential in the modern multidisciplinary
management of cirrhotic patients with AVH. Endoscopy
should not be delayed for more than 15 hours as it
is associated with increased risk of in-hospital mortality,
although otherwise the data is insuﬃcient for embracing
“the sooner the better” belief, particularly in hemody-
namically stable patients. Active bleeding at endoscopy in
decompensated cirrhotic patients predicts poor outcomes
and may warrant more aggressive treatment, such as early
TIPS right after endoscopic therapy. Band ligation is the
endoscopic modality of choice in primary prophylaxis,
hemostasis of active bleeding, and secondary prophylaxis of
EV bleeding. Although occasionally sclerotherapy may still
be performed for hemostatic control of acute EV bleeding,6 International Journal of Hepatology
it should no longer be used in the prophylactic setting.
Tissue glue injection to attain variceal obliteration is now
the preferred endoscopic therapy to control and prevent
bleeding from fundic and isolated GV. The paucity of data in
the management of GV warrants more research, particularly
large controlled trials, to deﬁne the evidence-based standard
of care. Even though substantial improvement has been
achieved for the last several decades in the management of
cirrhotic patients with AVH, there is undoubtedly plenty
room for continuing improvement in this still highly lethal
medical emergency.
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